Meglumine

Overview

Meglumine Antimoniate is used for many diagnostic test in different concentrations such as 85% injection is used for adult angiocardiography and thoracic aortography and a 76% solution is used in excretion urography, paediatric angiocardiography and Meglumine Diatrizoate, Sodium and Sodium Meglumine is used for angiocardiography and thoracic aortography in different concentrations. Meglumine Iodoxamate is the methylglucamine salt of an ionic, water-soluble, dimeric, radiographic contrast medium; formerly used primarily for intravenous cholangiography.

Categories

Primary Characterstics

Meglumine is also known as Dimeglumine. Meglumine gadopentetate, Meglumine gadopentetate, Meglumine gadopentetate, Meglumine gadopentetate, Meglumine gadopentetate are the derivatives of MeglumineMeglumine is also known as Dimeglumine. Meglumine gadopentetate, Meglumine gadopentetate, Meglumine gadopentetate, Meglumine gadopentetate, Meglumine gadopentetate are the derivatives of Meglumine It is of Synthetic origin and belongs to Methylglucamine sodium. It belongs to Radiopaque Agents and Diagnostic Aids pharmacological group.The Molecular Weight of Meglumine is 195.20.

It is weakly alkaline drug, 10.55% solution of the drug is isotonic.

Indications

Meglumine is primarily indicated in conditions like Angiography, Arthrography, Cholangiography, Cholecystography, CT enhancement, Cutaneous leishmaniasis, Duodenal ulcer associated with h. Pylori, Excretion urography, Radiological contrast agent, Splenoportography, Venography.

Back to top

Pharmacokinetics

Back to top

Contraindications

Back to top

Drug Interactions

Back to top

Side Effects

The severe or irreversible adverse effects of Meglumine, which give rise to further complications include Pancreatitis, Impaired renal function, Hyperthyroidism.

Meglumine produces potentially life-threatening effects which include Anaphylactoid reactions, Ventricular fibrillation, Pulmonary edema, Cardiac arrhythmias, Angioneurotic edema. which are responsible for the discontinuation of Meglumine therapy.

The signs and symptoms that are produced after the acute overdosage of Meglumine include Bradycardia, Hypotension, Anaphylactoid reactions, Pyrexia, Renal failure, Tremor.

The symptomatic adverse reactions produced by Meglumine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Diarrhea, Fever, Abdominal pain, Chills, Rashes, Urticaria, Colitis, Itching, Hypotension, Flushing, Muscle weakness, Nausea and vomiting, Sneezing, Altered taste sensations, Faintness, Hypertension, Nodular goitre, Enteritis.

Back to top

Dosage

Meglumine's dosage details are as follows:
Dose Single Dose Frequency Route Instructions

Adult Dosage

Consult your physcian.

Paedriatic Dosage (20kg)

No data regarding the Paedriatic dosage details of Meglumine is available.

Neonatal Dosage (3kg)

No data regarding the neonatal dosage details of Meglumine is available.

High Risk Groups

Back to top

Warning / Precautions

Back to top

Storage Conditions

Inj

Protect from Sunlight.

Back to top

Interference in Pathology

  • Thyroid Function Test
  • Sulphosalicylic acid test for urinary protein.
  • Falsely alkaptonuria results with cupric sulphate urinary glucose test.

Back to top

Brands / Trade Names of Meglumine

Back to top

Manufacturers of Meglumine in Pakistan

Back to top

Previous Drug Generic - Next Drug Generic


Suggested Pages